Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Prepaid Assets (2022 - 2026)

Kura Oncology has reported Prepaid Assets over the past 5 years, most recently at $32.8 million for Q1 2026.

  • Quarterly Prepaid Assets rose 89.84% to $32.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $32.8 million through Mar 2026, up 89.84% year-over-year, with the annual reading at $32.2 million for FY2025, 109.48% up from the prior year.
  • Prepaid Assets was $32.8 million for Q1 2026 at Kura Oncology, up from $32.2 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $35.1 million in Q3 2025 and troughed at $7.3 million in Q3 2023.
  • The 5-year median for Prepaid Assets is $10.6 million (2023), against an average of $16.3 million.
  • Year-over-year, Prepaid Assets dropped 4.82% in 2024 and then soared 344.27% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $8.4 million in 2022, then grew by 0.98% to $8.5 million in 2023, then skyrocketed by 80.36% to $15.4 million in 2024, then skyrocketed by 109.48% to $32.2 million in 2025, then rose by 1.75% to $32.8 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Prepaid Assets are $32.8 million (Q1 2026), $32.2 million (Q4 2025), and $35.1 million (Q3 2025).